Correlation Between Akari Therapeutics and Equillium

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Akari Therapeutics and Equillium at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Akari Therapeutics and Equillium into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Akari Therapeutics PLC and Equillium, you can compare the effects of market volatilities on Akari Therapeutics and Equillium and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Akari Therapeutics with a short position of Equillium. Check out your portfolio center. Please also check ongoing floating volatility patterns of Akari Therapeutics and Equillium.

Diversification Opportunities for Akari Therapeutics and Equillium

0.29
  Correlation Coefficient

Modest diversification

The 3 months correlation between Akari and Equillium is 0.29. Overlapping area represents the amount of risk that can be diversified away by holding Akari Therapeutics PLC and Equillium in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Equillium and Akari Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Akari Therapeutics PLC are associated (or correlated) with Equillium. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Equillium has no effect on the direction of Akari Therapeutics i.e., Akari Therapeutics and Equillium go up and down completely randomly.

Pair Corralation between Akari Therapeutics and Equillium

Given the investment horizon of 90 days Akari Therapeutics PLC is expected to under-perform the Equillium. But the stock apears to be less risky and, when comparing its historical volatility, Akari Therapeutics PLC is 1.04 times less risky than Equillium. The stock trades about -0.21 of its potential returns per unit of risk. The Equillium is currently generating about 0.0 of returns per unit of risk over similar time horizon. If you would invest  87.00  in Equillium on September 13, 2024 and sell it today you would lose (17.00) from holding Equillium or give up 19.54% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthVery Weak
Accuracy100.0%
ValuesDaily Returns

Akari Therapeutics PLC  vs.  Equillium

 Performance 
       Timeline  
Akari Therapeutics PLC 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Akari Therapeutics PLC has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors.
Equillium 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Equillium has generated negative risk-adjusted returns adding no value to investors with long positions. Even with relatively invariable basic indicators, Equillium is not utilizing all of its potentials. The current stock price agitation, may contribute to short-term losses for the retail investors.

Akari Therapeutics and Equillium Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Akari Therapeutics and Equillium

The main advantage of trading using opposite Akari Therapeutics and Equillium positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Akari Therapeutics position performs unexpectedly, Equillium can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Equillium will offset losses from the drop in Equillium's long position.
The idea behind Akari Therapeutics PLC and Equillium pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.

Other Complementary Tools

AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
CEOs Directory
Screen CEOs from public companies around the world
Transaction History
View history of all your transactions and understand their impact on performance
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum